ProCE Banner Activity

An Expert’s Guide to ASCO 2023: Preview of the Top Abstracts

Conference Coverage
Clinical Thought

Experts highlight their choice of key studies being presented at the 2023 ASCO Annual Meeting. CCO’s Independent Conference Coverage will include timely summaries, expert analysis, and practical implications of the latest research and developments in oncology to help you stay at the forefront of advances in cancer care.

Released: June 01, 2023

Share

Faculty

Erika P. Hamilton

Erika P. Hamilton, MD

Director, Breast Cancer Research Program
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, Tennessee

Shaji K. Kumar

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Chair, Myeloma Amyloidosis Dysproteinemia Group
Consultant, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Christopher H. Lieu

Christopher H. Lieu, MD

Associate Professor
Associate Director for Clinical Research
Division of Medical Oncology
University of Colorado Cancer Center
Co-Director, GI Medical Oncology
Division of Medical Oncology
University of Colorado Hospital
Aurora, Colorado

Jason J. Luke

Jason J. Luke, MD, FACP

Associate Professor
Hematology/Oncology
University of Pittsburgh
Pittsburgh, Pennsylvania

Lauren Prescott

Lauren Prescott, MD, MPH

Assistant Professor, Obstetrics and Gynecology
Division of Gynecologic Oncology
Vanderbilt University Medical Center
Nashville, Tennessee

Karen Reckamp

Karen Reckamp, MD, MS

Professor in Medicine
Director, Division of Medical Oncology
Associate Director, Clinical Research
Cedars-Sinai Medical Center
Los Angeles, California

Ritu Salani

Ritu Salani, MD, MBA

Professor and Division Director
Division of Gynecologic Oncology
Department of Obstetrics and Gynecology
University of California, Los Angeles
Los Angeles, California

Jeffrey P. Sharman

Jeffrey P. Sharman, MD

Medical Director
Hematology Research
Willamette Valley Cancer Institute
US Oncology
Eugene, Oregon

Rachna Shroff

Rachna Shroff, MD, MS

Professor of Medicine
Interim Chief, Division of Hematology/Oncology
University of Arizona Cancer Center
Tucson, Arizona

Sara M. Tolaney

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Heather Wakelee

Heather Wakelee, MD, FASCO

Professor of Medicine
Department of Medicine/Oncology
Stanford University
Stanford University Cancer Institute
Stanford, California 

Eunice S. Wang

Eunice S. Wang, MD

Chief, Leukemia/Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Jeffrey S. Weber

Jeffrey S. Weber, MD, PhD

Professor of Medicine
NYU Grossman School of Medicine
Deputy Director
NYU Langone Health
Laura and Isaac Perlmutter Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Disclosure

Primary Author

Erika P. Hamilton, MD

Director, Breast Cancer Research Program
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, Tennessee

Erika Hamilton, MD: consultant/advisor: Arcus, AstraZeneca, Daiichi Sankyo, Ellipses Pharma, Greenwich LifeSciences, iTeos, Janssen, Lilly, Loxo, Mersana, Novartis, Olema Pharmaceuticals, Orum Therapeutics, Pfizer, Relay Therapeutics, Roche/Genentech, Seagen, Stemline Therapeutics, Tubulis, Verascity Science; researcher (paid to institution): AbbVie, Acerta Pharma, Accutar Biotechnology, ADC Therapeutics, Akesobio Australia, Amgen, Aravive, ArQule, Artios, Arvinas, AstraZeneca, AtlasMedx, BeiGene, Black Diamond, Bliss Biopharmaceuticals, Boehringer Ingelheim, Cascadian Therapeutics, Clovis, Compugen, Context Therapeutics, Cullinan-Florentine, Curis, CytomX, Daiichi Sankyo, Dana Farber Cancer Inst, Dantari, Deciphera, Duality Biologics, eFFECTOR Therapeutics, Ellipses Pharma, Elucida Oncology, EMD Serono, FujiFilm, G1 Therapeutics, H3 Biomedicine, Harpoon, Hutchinson MediPharma, Immunogen, Immunomedics, Incyte, Infinity Pharmaceuticals, InventisBio, Jacobio, Karyopharm, K-Group Beta, Kind Pharmaceuticals, Leap Therapeutics, Lilly, Loxo Oncology, Lycera, Mabspace Biosciences, Macrogenics, MedImmune, Mersana, Merus, Millennium, Molecular Templates, Novartis, Nucana, Olema, OncoMed, Onconova Therapeutics, Oncothyreon, ORIC Pharmaceuticals, Orinove, Orum Therapeutics, Pfizer, PharmaMar, Pieris Pharmaceuticals, Pionyr Immunotherapeutics, Plexxikon, Prelude Therapeutics, Profound Bio, Radius Health, Regeneron, Relay Therapeutics, Repertoire Immune Medicine, Rgenix, Roche/Genentech, Seagen, Sermonix Pharmaceuticals, Shattuck Labs, StemCentRx, Sutro, Syndax, Syros, Taiho, TapImmune, Tesaro, Tolmar, Torque Therapeutics, Treadwell Therapeutics, Verastem, Zenith Epigenetics, Zymeworks.

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Chair, Myeloma Amyloidosis Dysproteinemia Group
Consultant, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Shaji Kumar, MD: consultant/advisor: AbbVie, Amgen, Antengene, Arcellx, AstraZeneca, BeiGene, Bluebird Bio, Bristol Myers Squibb, Janssen, Roche-Genentech, K36, Loxo Oncology, Oncopeptides, Pfizer, Sanofi, Secura Biotherapeutics, Takeda; researcher: AbbVie, Allogene, Amgen, AstraZeneca, Bristol Myers Squibb, Carsgen, GSK, Janssen, Regeneron, Roche-Genentech, Takeda.

Christopher H. Lieu, MD

Associate Professor
Associate Director for Clinical Research
Division of Medical Oncology
University of Colorado Cancer Center
Co-Director, GI Medical Oncology
Division of Medical Oncology
University of Colorado Hospital
Aurora, Colorado

Christopher H. Lieu, MD: researcher: Merck.

Jason J. Luke, MD, FACP

Associate Professor
Hematology/Oncology
University of Pittsburgh
Pittsburgh, Pennsylvania

Jason Luke, MD, FACP: consultant/advisor/speaker: 7 Hills, AbbVie, Actym, Affivant, Agenus, Alnylam, Alphamab Oncology, Arch Oncology, Atomwise, Bayer, BioCytics, Bright Peak, Bristol Myers Squibb, Castle, Checkmate, Codiak, Crown, Cugene, Curadev, Day One, Duke Street Bio, EMD Serono, Eisai, Endeavor, Exo, Flame, Fstar, G1 Therapeutics, Genentech, Gilead, Glenmark, HotSpot, IO Biotech, Ikena, Immatics, Immunocore, Incyte, Instil, Inzen, Janssen, KSQ, Kadmon, Kanaph, Macrogenics, Mavu, Merck, Mersana, Nektar, NeoTx, Novartis, Onc.AI, OncoNano, Partner, Pfizer, Pioneering Medicines, physIQ, PsiOxus, Pyxis, RefleXion, Regeneron, Replimmune, Ribon, Roivant, STINGthera, STipe, Saros, Servier, Synlogic, Synthekine, Tempest, Xilio; research support (paid to institution): AbbVie, Astellas, AstraZeneca, Bristol Myers Squibb, Corvus, Day One, EMD Serono, Fstar, Genmab, Ikena, Immatics, Incyte, Kadmon, KAHR, Macrogenics, Merck, Moderna, Nektar, Next Cure, Numab, Palleon, Pfizer, Replimune, Rubius, Servier, Scholar Rock, Synlogic, Takeda, Trishula, Tizona, Xencor; data safety monitoring board: AbbVie, Agenus, Immutep, Evaxion; royalties or patent beneficiary (both provisional): serial #15/612,657 (Cancer Immunotherapy), PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof); individual publicly traded stocks and stock options: Actym, Alphamab Oncology, Arch Oncology, Duke Street Bio, Kanaph, Mavu, NeoTx, Onc.AI, OncoNano, physIQ, Pyxis, Saros, STipe, Tempest; consultant: AbbVie, Agenus, Alnylam, Atomwise, Bayer, Bristol Myers Squibb, Castle, Checkmate, Codiak, Crown, Cugene, Curadev, Day One, Eisai, EMD Serono, Endeavor, Flame, G1 Therapeutics, Genentech, Gilead, Glenmark, HotSpot, Kadmon, KSQ, Janssen, Ikena, Inzen, Immatics, Immunocore, Incyte, Instil, IO Biotech, Macrogenics, Merck, Mersana, Nektar, Novartis, Partner, Pfizer, Pioneering Medicines, PsiOxus, Regeneron, Replimune, Ribon, Roivant, Servier, STINGthera, Synlogic, Synthekine.

Lauren Prescott, MD, MPH

Assistant Professor, Obstetrics and Gynecology
Division of Gynecologic Oncology
Vanderbilt University Medical Center
Nashville, Tennessee

Lauren Prescott, MD, has no relevant financial relationships to disclose.

Karen Reckamp, MD, MS

Professor in Medicine
Director, Division of Medical Oncology
Associate Director, Clinical Research
Cedars-Sinai Medical Center
Los Angeles, California

Karen Reckamp, MD: consultant/advisor/speaker: Amgen, AstraZeneca, Blueprint, Daiichi Sankyo, EMD Serono, Genentech, GSK, Janssen, Lilly, Mirati; research funding (paid to institution): Blueprint, Calithera, Daiichi Sankyo, Elevation, Genentech, Janssen.

Ritu Salani, MD, MBA

Professor and Division Director
Division of Gynecologic Oncology
Department of Obstetrics and Gynecology
University of California, Los Angeles
Los Angeles, California

Ritu Salani, MD, MBA: consultant/advisor/speaker: GSK, Merck, Regeneron, Seagen.

Jeffrey P. Sharman, MD

Medical Director
Hematology Research
Willamette Valley Cancer Institute
US Oncology
Eugene, Oregon

Jeffrey P. Sharman, MD: consultant/advisor/speaker: AbbVie, ADC Therapeutics, AstraZeneca, BeiGene, Bristol Myers Squibb, Genentech, Janssen, Lilly, Merck.

Rachna Shroff, MD, MS

Professor of Medicine
Interim Chief, Division of Hematology/Oncology
University of Arizona Cancer Center
Tucson, Arizona

Rachna T. Shroff, MD, MS: consultant/advisor/speaker: Astellas, AstraZeneca, Boehringer Ingelheim, Clovis, Genentech, Incyte, Merck, QED, Servier, Syros, Taiho, Zymeworks; researcher: Bayer, Bristol Myers Squib, IMV, Loxo, Merck, Novocure, NuCana, Pieris, QED, Rafael, Seagen, Taiho. 

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Sara Tolaney, MD, MPH: consultant/advisor: 4D Pharma, Aadi Biopharma, ARC Therapeutics, Artios Pharma, AstraZeneca, Bayer, BeyondSpring Pharmaceuticals, Blueprint Medicines, Bristol Myers Squibb, CytomX Therapeutics, Daiichi Sankyo, Eisai, Ellipses Pharma, Genentech/Roche, Gilead, Incyte Corp, Infinity Therapeutics, Jazz Pharmaceuticals, Lilly, Menarini/Stemline, Merck, Myovant, Novartis, OncoSec Medical Inc., OncXerna, Pfizer, Reveal Genomics, Sanofi, Seattle Genetics, Umoja Biopharma, Zentalis, Zetagen, Zymeworks; researcher (paid to institution): AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Genentech/Roche, Gilead, Gilead, Lilly, Merck, NanoString Technologies, Novartis, OncoPep, Pfizer, Seattle Genetics.

Heather Wakelee, MD, FASCO

Professor of Medicine
Department of Medicine/Oncology
Stanford University
Stanford University Cancer Institute
Stanford, California 

Heather Wakelee, MD, FASCO: consultant/advisor/speaker: Mirati; researcher: AstraZeneca, Bayer, Bristol-Myers Squibb, Clovis, Genentech/Roche, Helsinn, Merck, SeaGen, Xcovery.

Eunice S. Wang, MD

Chief, Leukemia/Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Eunice S. Wang, MD: consultant/advisor/speaker: AbbVie, Amgen, Astellas, Bristol Myers Squibb, Celgene, Daiichi Sankyo, Genentech, Gilead, GlaxoSmithKline, Janssen, Jazz, Kite, Kura Oncology, Mana Therapeutics, Novartis, Pfizer, PharmaEssentia, NuProbe, Rafael, Stemline, Takeda.

Jeffrey S. Weber, MD, PhD

Professor of Medicine
NYU Grossman School of Medicine
Deputy Director
NYU Langone Health
Laura and Isaac Perlmutter Cancer Center
New York, New York

Jeffrey S. Weber, MD, PhD: consultant/advisor/speaker: AstraZeneca, Bristol Myers Squibb, Genentech, GlaxoSmithKline, Incyte, Merck, Moderna, Pfizer, Regeneron.